EASL Press Conference 2019 Upload video: No flash player has been set up. Please select a player to play Flash videos.
07Mar, 19MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D InfectionsMYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has...
10Mar, 14Press Release, Moscow, March 11th, 2014MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF...
15Mar, 12Press Release, Moscow, March 15th, 2012Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program Co-Invests with Germany’s Public/Private...
29Oct, 18MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta at the AASLD Meeting in San FranciscoBAD HOMBURG, Germany, October 29, 2018 / PRNewswire / -- MYR Pharma today announced that the results of 48 weeks of...
23Oct, 18MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D InfectionsMYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation...
30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
